Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Sells $358,371.45 in Stock

Key Points

• Major shareholder 5AM Ventures sold 52,317 Entrada Therapeutics shares at an average price of $6.85, generating $358,371.45. The sale reduced its position by 1.84%, leaving it with 2.78 million shares.
• Entrada shares rose 1.2% to $6.95, but the company reported a quarterly loss of $1.01 per share and revenue of $0.90 million, missing analysts’ expectations on both measures.
• Analysts have a consensus rating of Hold with a $17.50 price target, while institutional investors and hedge funds own 86.39% of the company’s stock.

Entrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) major shareholder Ventures L.P. 5Am sold 52,317 shares of the company's stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $6.85, for a total value of $358,371.45. Following the transaction, the insider directly owned 2,783,781 shares of the company's stock, valued at approximately $19,068,899.85. This trade represents a 1.84% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Major shareholders that own at least 10% of a company's shares are required to disclose their transactions with the SEC.

Entrada Therapeutics Trading Up 1.2%

Shares of NASDAQ TRDA traded up $0.08 during midday trading on Monday, reaching $6.95. The company's stock had a trading volume of 411,770 shares, compared to its average volume of 464,800. The stock has a 50 day simple moving average of $6.86 and a 200-day simple moving average of $9.68. The stock has a market capitalization of $270.63 million, a price-to-earnings ratio of -1.76 and a beta of -0.26. Entrada Therapeutics, Inc. has a fifty-two week low of $4.93 and a fifty-two week high of $16.45.

Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported ($1.01) earnings per share for the quarter, missing analysts' consensus estimates of ($0.97) by ($0.04). Entrada Therapeutics had a negative net margin of 3,537.73% and a negative return on equity of 57.61%. The business had revenue of $0.90 million during the quarter, compared to the consensus estimate of $2.32 million. As a group, equities analysts anticipate that Entrada Therapeutics, Inc. will post -4.07 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on TRDA. Weiss Ratings cut shares of Entrada Therapeutics from a "sell (d)" rating to a "sell (d-)" rating in a report on Thursday, June 11th. Guggenheim lowered their price objective on Entrada Therapeutics from $20.00 to $17.00 and set a "buy" rating on the stock in a research note on Monday, June 8th. Roth Capital set a $10.00 target price on Entrada Therapeutics in a research report on Friday, May 8th. Finally, HC Wainwright lowered Entrada Therapeutics from a "buy" rating to a "neutral" rating in a report on Friday, May 8th. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $17.50.

Institutional Investors Weigh In On Entrada Therapeutics

Several hedge funds have recently modified their holdings of TRDA. State of Wyoming bought a new stake in Entrada Therapeutics during the 2nd quarter worth $37,000. Russell Investments Group Ltd. raised its position in Entrada Therapeutics by 72.7% in the third quarter. Russell Investments Group Ltd. now owns 8,808 shares of the company's stock valued at $51,000 after purchasing an additional 3,707 shares during the last quarter. Occudo Quantitative Strategies LP acquired a new stake in shares of Entrada Therapeutics during the second quarter valued at about $68,000. Jain Global LLC acquired a new stake in shares of Entrada Therapeutics during the third quarter valued at about $69,000. Finally, IHT Wealth Management LLC bought a new stake in shares of Entrada Therapeutics during the second quarter worth about $72,000. Institutional investors and hedge funds own 86.39% of the company's stock.

Entrada Therapeutics Company Profile

Entrada Therapeutics NASDAQ: TRDA is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company's pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source